Changjiang Runfa Medicine Co Ltd operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Changjiang Runfa Medicine Co Ltd with three other
companies in this sector in China:
Shenzhen Hepalink Pharmaceutical Group Co Ltd
sales of 4.81 billion Chinese Renmimbi [US$678.66 million]
of which 100%
was Pharmaceutical Manufacturing),
Tianjin Chase Sun Pharmaceutical Company Limited
(4.22 billion Chinese Renmimbi [US$595.41 million]
of which 51%
was Granules), and
Shandong Xinhua Pharmaceutical Company Limited
(5.21 billion Chinese Renmimbi [US$734.10 million]
of which 49%
During the year ended December of 2018, sales at
Changjiang Runfa Medicine Co Ltd were 4.67 billion Chinese Renmimbi (US$658.81 million).
increase of 56.5%
versus 2017, when the company's sales were 2.99 billion Chinese Renmimbi.
This was the third consecutive year of growth at Changjiang Runfa Medicine Co Ltd.